Accelrys Non-compliant with Nasdaq Listing Rule | GenomeWeb

NEW YORK (GenomeWeb News) – Accelrys said on Friday that it has been notified by Nasdaq that the company does not comply with a listing requirement that its audit committee be comprised of three independent directors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.